New hope for kids with rare cancers: Three-Drug combo under study
NCT ID NCT05407441
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 26 times
Summary
This study tests a combination of three drugs—tazemetostat, nivolumab, and ipilimumab—for children with rare tumors that lack certain proteins (INI1 or SMARCA4). The goal is to find safe doses and see if the drugs shrink tumors. About 49 children with specific cancers like atypical teratoid rhabdoid tumor or epithelioid sarcoma are participating.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATYPICAL TERATOID/RHABDOID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Boston Children's Hospital
Boston, Massachusetts, 02115, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Texas Children's Hospital
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.